These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 14713978)
1. [Pulmonary arterial hypertension treated with prostacyclin or calcium blockers]. Andreassen AK; Geiran O; Madsen S; Hognestad A; Simonsen S Tidsskr Nor Laegeforen; 2003 Dec; 123(23):3393-6. PubMed ID: 14713978 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension. Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700 [TBL] [Abstract][Full Text] [Related]
3. [Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin. Long-term results]. Jiménez López-Guarch C; Escribano Subias P; Tello de Meneses R; Delgado Jiménez JF; Sadia Pérez D; Velázquez Martín MT; Gómez Sánchez MA; Sáenz de la Calzada C Rev Esp Cardiol; 2004 Oct; 57(10):946-51. PubMed ID: 15469792 [TBL] [Abstract][Full Text] [Related]
4. [Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis]. Olschewski H; Ghofrani HA; Walmrath D; Schermuly R; Temmesfeld-Wollbrück B; Grimminger F; Seeger W Pneumologie; 2000 Mar; 54(3):133-42. PubMed ID: 10783653 [TBL] [Abstract][Full Text] [Related]
5. [Effects of long-term treatment with prostacyclin on plasma adrenomedullin in patients with primary pulmonary hypertension]. Nakayama T; Ishikita T; Matsuura H; Saji T J Cardiol; 2001 Nov; 38(5):263-71. PubMed ID: 11729726 [TBL] [Abstract][Full Text] [Related]
6. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477 [TBL] [Abstract][Full Text] [Related]
7. Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension. Kähler CM; Graziadei I; Wiedermann CJ; Kneussl MP; Vogel W Wien Klin Wochenschr; 2000 Jul; 112(14):637-40. PubMed ID: 11008327 [TBL] [Abstract][Full Text] [Related]
8. [Nebulized prostacyclin treatment for pulmonary hypertension in a 2-year-old girl]. Puigarnau Vallhonrat R; Pons Odena M; Carballo Ruano E An Esp Pediatr; 2000 Oct; 53(4):372-6. PubMed ID: 11083992 [TBL] [Abstract][Full Text] [Related]
9. Sustained improvement of performance and haemodynamics with long-term aerosolised prostacyclin therapy in severe pulmonary hypertension. Stricker H; Domenighetti G; Fiori G; Mombelli G Schweiz Med Wochenschr; 1999 Jun; 129(24):923-7. PubMed ID: 10413827 [TBL] [Abstract][Full Text] [Related]
12. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Sitbon O; McLaughlin VV; Badesch DB; Barst RJ; Black C; Galiè N; Humbert M; Rainisio M; Rubin LJ; Simonneau G Thorax; 2005 Dec; 60(12):1025-30. PubMed ID: 16055621 [TBL] [Abstract][Full Text] [Related]
13. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. McLaughlin VV; Genthner DE; Panella MM; Rich S N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406 [TBL] [Abstract][Full Text] [Related]
14. Bosentan: new preparation. Pulmonary hypertension: an option before epoprostenol infusion. Prescrire Int; 2005 Apr; 14(76):47-50. PubMed ID: 15875338 [TBL] [Abstract][Full Text] [Related]
15. EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. Sitbon O; Delcroix M; Bergot E; Boonstra AB; Granton J; Langleben D; Subías PE; Galiè N; Pfister T; Lemarié JC; Simonneau G Am Heart J; 2014 Feb; 167(2):210-7. PubMed ID: 24439982 [TBL] [Abstract][Full Text] [Related]
16. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation. Conte JV; Gaine SP; Orens JB; Harris T; Rubin LJ J Heart Lung Transplant; 1998 Jul; 17(7):679-85. PubMed ID: 9703232 [TBL] [Abstract][Full Text] [Related]
17. A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients. Khan TA; Schnickel G; Ross D; Bastani S; Laks H; Esmailian F; Marelli D; Beygui R; Shemin R; Watson L; Vartapetian I; Ardehali A J Thorac Cardiovasc Surg; 2009 Dec; 138(6):1417-24. PubMed ID: 19931670 [TBL] [Abstract][Full Text] [Related]